Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease

被引:11
作者
Aurer, I
Radman, I
Nemet, D
Zupancic-Salek, S
Bogdanic, V
Mrsic, M
Sertic, D
Labar, B
机构
[1] Univ Hosp Ctr Rebro, Dept Internal Med, Div Hematol, Zagreb 10000, Croatia
[2] Sch Med, Zagreb, Croatia
来源
ONKOLOGIE | 2005年 / 28卷 / 11期
关键词
Hodgkin's disease; relapse; gemcitabine;
D O I
10.1159/000088621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients with refractory Hodgkin's disease or relapsing after high-dose therapy and autografting have a poor prognosis. Here, we present our experiences with gemcitabine in this setting. Patients and Methods: We treated 14 patients with relapsed or refractory Hodgkin's disease with gemcitabine. The treatment was given on a compassionate use basis, off-label and not according to a study protocol. Patients were 17 - 46 years of age. 1 patient had stage IA disease, 2 patients had stage IIIB disease and 11 patients had stage IVB disease. 9 patients had received radiotherapy. 8 patients had been autografted and 1 patient auto- and allografted. Gemcitabine was administered at a starting dose of 1 g/m(2) on days 1 and 8 every 3 weeks in combination with steroids. Results: The median follow-up period was 10 months. Hematological toxicity grade 3 - 4 occurred in 12 patients leading to dose reductions. 1 patient died of neutropenic sepsis. No other non-hematological toxicities were observed. The response rate was 64% with 6 patients achieving complete remission (CR) and 3 patients partial remission (PR). The median time to treatment failure was 9 months, and survival was 11 months. Responses were seen in previously transplanted patients and in patients refractory to previous treatment. The so far longest responder has been in CR for over 68 months. Conclusion: Gemcitabine is an effective treatment for Hodgkin's disease. Heavily pretreated patients often require dose reductions.
引用
收藏
页码:567 / 571
页数:5
相关论文
共 24 条
[1]   Involved-field radiotherapy for advanced Hodgkin's lymphoma [J].
Aleman, BMP ;
Raemaekers, JMM ;
Tirelli, U ;
Bortolus, R ;
van't Veer, MB ;
Lybeert, MLM ;
Keuning, JJ ;
Carde, P ;
Girinsky, T ;
van der Maazen, RWM ;
Tomsic, R ;
Vovk, M ;
van Hoof, A ;
Demeestere, G ;
Lugtenburg, PJ ;
Thomas, J ;
Schroyens, W ;
De Boeck, K ;
Baars, JW ;
Kluin-Nelemans, JC ;
Carrie, C ;
Aoudjhane, M ;
Bron, D ;
Eghbali, H ;
Smit, WGJM ;
Meerwaldt, JH ;
Hagenbeek, A ;
Pinna, A ;
Henry-Amar, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2396-2406
[2]   German Hodgkin's Lymphoma Study Group (DHSG):: 20 years experience with diagnostics, therapy and aftercare in patients with Hodgkin's disease [J].
Ansén, S ;
Engert, A ;
Wolf, J ;
Sieber, M ;
Paulus, U ;
Diehl, V .
ONKOLOGIE, 2001, 24 :35-48
[3]   Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].
Baetz, T ;
Belch, A ;
Couban, S ;
Imrie, K ;
Yau, J ;
Myers, R ;
Ding, K ;
Paul, N ;
Shepherd, L ;
Iglesias, J ;
Meyer, R ;
Crump, M .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767
[4]   External cephalic version of twin A [J].
Bloomfield, MM ;
Philipson, EH .
OBSTETRICS AND GYNECOLOGY, 1997, 89 (05) :814-815
[5]   Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin:: A report of the German Hodgkin's lymphoma Study Group [J].
Bredenfeld, H ;
Franklin, J ;
Nogova, L ;
Jesting, A ;
Fries, S ;
Mailänder, V ;
Oertel, J ;
Diehl, V ;
Engert, A .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2424-2429
[6]  
Carde P, 1997, P AN M AM SOC CLIN, V16, p13a
[7]   Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma [J].
Chau, I ;
Harries, M ;
Cunningham, D ;
Hill, M ;
Ross, PJ ;
Archer, CD ;
Norman, AR ;
Wotherspoon, A ;
Koh, DM ;
Gill, K ;
Uzzell, M ;
Prior, Y ;
Catovsky, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :970-977
[8]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[9]  
CSOKA K, 1995, SEMIN ONCOL, V22, P47
[10]   Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial [J].
Duggan, DB ;
Petroni, GR ;
Johnson, JL ;
Glick, JH ;
Fisher, RI ;
Connors, JM ;
Canellos, GP ;
Peterson, BA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :607-614